143 Does vitamin d prophylaxis prevent adverse neonatal outcomes

To determine if Vitamin D prophylaxis prevents adverse neonatal outcomes. A secondary analysis assessing neonatal outcomes was performed on a randomized control trial in which pregnant women received Vitamin D3 3000 IU daily or no supplement. Maternal 25-hydroxyvitamin D (25(OH)D) levels were assessed at the time of enrollment and admission for delivery. Neonatal 25(OH)D) level was assessed via cord blood. Neonatal outcomes collected included gestational age at delivery, birthweight, need for NICU admission, respiratory distress, neonatal infection/sepsis, and pregnancy loss. Parametric and nonparametric statistics were used to compare groups. A P value of <0.05 was statistically significant. Enrollment occurred between October 2016 and September 2019. Of the 412 women enrolled, 392 (95.1%) had completed pregnancies for analysis. Demographic characteristics including baseline maternal 25-hydroxyvitamin D (25(OH)D) levels were similar between groups. Table 1. Compared to women who did not receive Vitamin D prophylaxis, those who did had a significantly higher 25(OH)D delivery serum level (29.18 ± 11.87 ng/mL vs. 23.79 ± 9.29 ng/mL; P<0.001) and cord blood level (33.73 ± 13.68 ng/mL vs. 26.06 ± 9.72 ng/mL; P<0.001). While vitamin D prophylaxis was not associated with a decreased incidence of preterm birth, low birth weight, NICU admission, respiratory distress and neonatal infection/sepsis, use was associated with a decreased incidence of pregnancy loss (0.5 vs. 4.1%; RR 0.1 (0.01-0.9); P=0.01) and a low 5 minute Apgar score at the time of birth (1.0 vs. 5.2%; RR 0.2 (0.1-0.8); P=0.02). Table 2. Vitamin D prophylaxis not only increases baseline maternal and neonatal 25(OH)D) levels, but is also associated with a lower incidence of pregnancy loss and higher Apgar scores.View Large Image Figure ViewerDownload Hi-res image Download (PPT)